L 374087

structure in first source
Also Known As:
L 373,087; L-374,087; L-374087
Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Szalony, James A: 1 article (10/2002)
2. Girard, Thomas J: 1 article (10/2002)
3. Taite, Beatrice B: 1 article (10/2002)
4. Nicholson, Nancy S: 1 article (10/2002)
5. LaChance, Rhonda M: 1 article (10/2002)

Related Diseases

1. Thrombosis (Thrombus)
04/01/1999 - "These results indicate significant antithrombotic efficacy against both venous and coronary arterial thrombosis with L-374,087 with only moderate elevations in aPTT or prothrombin time. "
04/01/1999 - "In anesthetized rhesus monkeys, 300 microgram/kg bolus plus 12 microgram/kg/min and 300 microgram/kg bolus plus 30 microgram/kg/min L-374,087 i.v. infusions significantly reduced jugular vein thrombus extension, with both regimens limiting venous thrombus extension to 2-fold that of baseline thrombus mass compared with a 5-fold extension observed in the vehicle control group. "
04/01/1999 - "The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. "
04/01/1999 - "In a conscious instrumented dog model of electrolytic vessel injury, the oral administration of two 10 mg/kg L-374,087 doses 12 h apart significantly reduced jugular vein thrombus mass, reduced the incidence of and delayed time to occlusive coronary artery thrombosis, and significantly reduced coronary artery thrombus mass and ensuing posterolateral myocardial infarct size. "
10/01/2002 - "The goal of this non-randomized study was to evaluate XK1, a specific protein inhibitor of TF/FVIIa, and compare antithrombotic efficacy and bleeding propensity to a previously described Factor Xa (FXa) inhibitor (SC-83157/SN429) and a direct-acting thrombin inhibitor (SC-79407/L-374087) in an acute rat model of arterial thrombosis. "
2. Hemorrhage
3. Myocardial Infarction

Related Drugs and Biologics

1. Thrombin
2. Factor Xa (Coagulation Factor Xa)
3. Thromboplastin (Tissue Factor)
4. glucuronyl glucosamine glycan sulfate (Vessel)

Related Therapies and Procedures

1. Oral Administration